# US 2014/0194375 A1 · Topical antibiotic composition for the prevention of lyme disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0194375 A1
- Document ID: US20140194375A1
- Status: Published application
- Kind: A1
- Application number: 14/208,491
- Filed: 2014-03-13
- Published: 2014-07-10
- Earliest claimed: 2007-07-25
- Assignees: Ixodes AG
- Applicants: Ixodes AG
- Inventors: Gustave HUBER; Huttenes UTA; Caroline ROOSENS-VON BIDDER
- Web page: https://patentgrep.com/patent/US20140194375A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61P 31/04: Antibacterial agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to topical pharmaceutical compositions and methods related to Borrelia burgdorferi toxins, in particular, the present invention provides compositions and methods for the treatment of infections caused by Borrelia burgdorferi and in particular for the prevention of Lyme disease.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A process for the preparation of a topical pharmaceutical composition for the prevention of Lyme disease comprising combining azithromycin, a solvent with greater volatility than water, a solvent less volatile than water, and a solidifying agent.

### Claim 14

A process for the preparation of a topical pharmaceutical composition for the elimination of Borrelia burgdorferi resulting from a tick bite comprising combining azithromycin, a solvent with greater volatility than water, a solvent less volatile than water, and a solidifying agent.

### Claim 15

A topical pharmaceutical composition for the prevention of Lyme disease or for the elimination of spirochetal, cystic and/or spherical forms of Borrelia burgdorferi resulting from a tick bite, comprising azithromycin, a solvent with greater volatility than water, a solvent less volatile than water, and a solidifying agent.

### Claim 16 (depends on 15)

The topical pharmaceutical composition according to claim 15, wherein the azithromycin is present from about 1 wt % to about 30 wt %, based on the total weight of the composition.

### Claim 17 (depends on 15)

The topical pharmaceutical composition according to claim 15, wherein the solvent with greater volatility than water is present from about 40 wt % to about 99 wt %, based on the total weight of the composition.

### Claim 18 (depends on 15)

The topical pharmaceutical composition according to claim 15, wherein the solidifying agent is present from about 5 wt % to about 60 wt %, based on the total weight of the composition.

### Claim 19 (depends on 15)

The topical pharmaceutical composition according to claim 15, wherein the solvent less volatile than water is present from about 2 wt % to about 30 wt %, based on the total weight of the composition.

### Claim 20 (depends on 15)

The topical pharmaceutical composition according to claim 15, comprising azithromycin base, acrylate/acrylamide copolymer, hydroxypropyl cellulose, medium chain triglycerides, and 94% ethanol.